GALT is expanding from its focus on NASH development to Oncology development with a shoestring Early data from a combo trial with MRK 's Prembolizumab in solid tumors recently showed promise This trial will enroll more patients The problem is that they only have enough cash to get into Q1/19 If efforts to find a partner for their NASH program are unsuccessful, GALT will likely to go the dilute-R/S-dilute route.